Phase 2 study of vascular endothelial growth factor trap for the treatment of metastatic thyroid cancer.

Eric J ShermanLara A DunnHeiko SchöderAlan L HoShrujal S BaxiRonald A GhosseinSofia S HaqueCami SimaRobert Michael TuttleDavid G Pfister

Published in: Cancer (2019)

Unlike TKIs, which have shown responses in this setting, to the authors' knowledge there have been no responses observed with the use of single-agent VT to date. It does not appear to be a promising drug for the treatment of patients with thyroid cancer.

Keyphrases

vascular endothelial growth factor
squamous cell carcinoma
healthcare
small cell lung cancer
endothelial cells
clinical trial
combination therapy
replacement therapy
study protocol